Floatz logo

Fluciclovine

Stage IVB Prostate Cancer AJCC v8

NRG OncologyradiopharmaceuticalPhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
89/ 100

Competitive context

513 Active assets in the Stage IVB Prostate Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
VIPIVOTIDE TETRAXETAN
Novartis Pharmaceuticals
Phase 4BB

View all 50 →

Same molecule, other indications

Fluciclovine is also rated in:

metastatic prostate carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
prostate carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
Male Urogenital DiseasesDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →